- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00743782
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prior studies (92-CH-0011) have been important in establishing synthetic human parathyroid hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with calcium and calcitriol. We are conducting a randomized crossover study comparing twice-daily subcutaneous injections vs. PTH pump therapy. We hypothesize that pump delivery of PTH 1-34, compared to twice-daily administration, will provide smoother metabolic control of serum mineral levels and normalization of urine mineral excretion. The two arms will be divided into an inpatient and an outpatient phase. There will be three inpatient admissions, baseline, 3 months, and 6 months. Subjects will be randomized to either pump therapy or to twice daily injections at the beginning of the study and will cross over to the alternate PTH delivery system (injections vs. pump) at the conclusion of the initial 3-month treatment period.
Patients between 10 and 70 years of age who have had chronic hypoparathyroidism for at least 1 year may be eligible for this study. Participants have two 10- 12-day hospital admissions and one 5-day admission. The first two inpatient admissions are separated by 3-month outpatient periods. Outpatient monitoring will require weekly blood tests and monthly urine tests to monitor mineral levels. After third hospital admission, patients will be placed on conventional therapy.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
This study will include patients of both genders (ages 7-70) with biochemically confirmed chronic hypoparathyroidism of at least one year duration. Twenty-four subjects will be enrolled.
EXCLUSION CRITERIA:
Subjects who meet any of the following criteria are not eligible for the study:
- Pregnancy
- Patients who are calcium infusion dependent and/or do not respond to calcitriol therapy to maintain normal levels of serum calcium will be excluded.
- Seizure disorder requiring antiepileptic medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Assess the feasability of PTH 1-34 therapy via pump.
|
Secondary Outcome Measures
Outcome Measure |
---|
This pilot study is being conducted to compare PTH therapy via pump vs. twice daily subcutaneous injections.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Karen K Winer, M.D., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Publications and helpful links
General Publications
- Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996 Aug 28;276(8):631-6.
- Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep;88(9):4214-20. doi: 10.1210/jc.2002-021736.
- Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008 Sep;93(9):3389-95. doi: 10.1210/jc.2007-2552. Epub 2008 May 20.
- Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010 Jun;95(6):2680-8. doi: 10.1210/jc.2009-2464. Epub 2010 Apr 14.
- Winer KK, Fulton KA, Albert PS, Cutler GB Jr. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr. 2014 Sep;165(3):556-63.e1. doi: 10.1016/j.jpeds.2014.04.060. Epub 2014 Jun 16.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Endocrine System Diseases
- Parathyroid Diseases
- Calcium Metabolism Disorders
- Water-Electrolyte Imbalance
- Hypoparathyroidism
- Hypocalcemia
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Calcium-Regulating Hormones and Agents
- Hormones
- Parathyroid Hormone
Other Study ID Numbers
- 080203
- 08-CH-0203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypocalcemia
-
Hospital Universitari de BellvitgeRecruitingIatrogenic HypocalcemiaSpain
-
Instituto PalaciosNexentia S.A.S.CompletedHypocalcemia; DietarySpain
-
Siriraj HospitalActive, not recruitingHypocalcemia in PregnancyThailand
-
Istanbul UniversityUnknownHypocalcemia, Postoperative ParathormoneTurkey
-
G. Hatzikosta General HospitalUnknownHypocalcemia After Total ThyroidectomyGreece
-
King Saud UniversityCompletedHypocalcemia | Hypomagnesemia | Hypomagnesemia With Secondary HypocalcemiaSaudi Arabia
-
Radboud University Medical CenterCompletedHypomagnesemia, Intestinal, With Secondary Hypocalcemia | Drug Induced Hypomagnesemia
-
Pak Emirates Military HospitalRecruiting
-
University of AlbertaWithdrawn
Clinical Trials on Synthetic Human Parathyroid Hormone 1-34
-
Massachusetts General HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoporosis | Postmenopausal OsteoporosisUnited States
-
Eli Lilly and CompanyTransPharma MedicalCompletedOsteoporosisHungary, Romania, Mexico, Argentina, Estonia
-
University of PittsburghWithdrawnHyperparathyroidism | Osteoporosis | Bone Diseases, Endocrine | Hypercalcemia of MalignancyUnited States
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Shane BurchEli Lilly and CompanyCompletedLumbar Spondylolisthesis | Lumbar Spondylosis | Adult Degenerative Lumbar ScoliosisUnited States
-
Massachusetts General HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of MiamiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
University of PittsburghNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperparathyroidism | Osteoporosis | Bone Diseases, EndocrineUnited States
-
National Institute of Diabetes and Digestive and...CompletedOsteoporosisUnited States
-
Eunice Kennedy Shriver National Institute of Child...CompletedHypoparathyroidismUnited States